A phase 1/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury.

Richard G Fessler,Reza Ehsanian,Charles Y Liu,Gary K Steinberg,Linda Jones,Jane S Lebkowski, Edward D Wirth,Stephen L McKenna

Journal of neurosurgery. Spine（2022）

引用 9|浏览14

暂无评分

摘要

LCTOPC1 can be safely administered to participants in the subacute period after cervical SCI. The injection procedure, low-dose temporary immunosuppression regimen, and LCTOPC1 were well tolerated. The safety and neurological function data support further investigation to determine the efficacy of LCTOPC1 in the treatment of SCI. Clinical trial registration no.: NCT02302157 (ClinicalTrials.gov).

查看译文

关键词

AST-OPC1,GRNOPC1,LCTOPC1,central nervous system,cervical spinal cord injury,clinical trials,human embryonic stem cells,trauma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要